Regan Mills, who holds the title of President, Product Test at Teradyne, INC (NASDAQ:TER), reported a sale of 16 shares of common stock on April 8, 2026, at a reported price of $342.17 per share, for an aggregate value of $5,474. That transaction was disclosed in a Form 4 filing submitted to the Securities and Exchange Commission.
The filing also notes an administrative correction related to the number of shares withheld by the issuer to satisfy the reporting person’s tax withholding obligations. Following that correction, an additional 16 shares were sold on April 8, 2026 under a sales plan the reporting person adopted on November 25, 2025. The sales plan was intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The filing does not provide additional pricing detail for the second 16-share sale beyond its occurrence on the same date.
After the transactions reported on the Form 4, Mills is recorded as directly owning 11,399.3452 shares of Teradyne, INC. The company’s share price sits close to a 52-week high of $358.69, and the stock has recorded a 353% increase over the past year.
On valuation metrics, Teradyne currently trades at a price-to-earnings ratio of 104.33. According to InvestingPro analysis cited in the disclosure, the stock appears overvalued relative to its Fair Value. InvestingPro coverage also notes that Teradyne is among the more than 1,400 U.S. equities covered by its Pro Research Reports.
Operationally, Teradyne has recently announced two new platforms. The Photon 100 is presented as an automated test platform for silicon photonics, while the Omnyx platform targets circuit board testing in data centers. Both platforms are described as being designed to support high-volume production and to address manufacturing challenges presented by complex assemblies.
Analyst commentary accompanying these product developments has been varied. Aletheia flagged a rebound in Taiwan’s tester imports, noting the potential to benefit Teradyne because of large orders for Rubin and networking-related testers. Morgan Stanley adjusted its price target for Teradyne to $306, citing stronger networking growth forecasts. Cantor Fitzgerald raised its target to $330, pointing to what it described as the company’s material shift toward artificial intelligence.
These corporate developments, analyst revisions, and the insider transactions occur as Teradyne’s shares trade near their yearly high and as third-party analysis raises valuation questions. The Form 4 filing and the company’s public disclosures provide the factual basis for the transactions and the related ownership information.
Additional context and disclosures: The Form 4 filing is the public record for the insider sale and the administrative correction referenced. The sales plan was adopted on November 25, 2025 and was intended to comply with Rule 10b5-1.